Insider · CIK 0001644137
Mark Baldry
Files at XFOR (X4 Pharmaceuticals, Inc). First filing Jan 27, 2025, latest May 20, 2025.
Mark Baldry files SEC Form 4 as officer at XFOR (X4 Pharmaceuticals, Inc). Since Jan 27, 2025, Mark Baldry has reported 2 open-market buys worth $22k and 1 open-market sell worth $13k, the latest filed on May 20, 2025.
A track record needs three past buys with six months of prices behind them; Mark Baldry has 0, so none is measured yet.
The newest scored trade: bought $2,561 of XFOR on May 16, 2025, filed May 20, 2025, scored 33 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XFOR: X4 Pharmaceuticals, Inc
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | XFORbuy X4 Pharmaceuticals, Inc | $2,561 1,032 shares | +4% | 0% from low-88% from high | |
| 21Weak | XFORbuy X4 Pharmaceuticals, Inc | $19k 35,050 shares | +37% | - | |
| 15Weak | X4 Pharmaceuticals, Inc | $13k 29,159 shares | -24% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 24, 2025 | XFOR X4 Pharmaceuticals, Inc | 29,159 0.02% of outstanding | $15k | Jan 24, 2025 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 16, 2025 | XFOR X4 Pharmaceuticals, Inc | AGrant or award Common Stock | +1,032 | $2.48 | $2,561 | 25,337 | Jun 3, 2025 |
| May 16, 2025 | XFOR X4 Pharmaceuticals, Inc | POpen-market purchase Common Stock | +1,032 | $2.48 | $2,561 | 25,337 | May 20, 2025 |
| May 17, 2024 | XFOR X4 Pharmaceuticals, Inc | POpen-market purchase Common Stock | +21,646 | $0.68 | $15k | 115,769 | Feb 14, 2025 |
| Nov 15, 2024 | XFOR X4 Pharmaceuticals, Inc | POpen-market purchase Common Stock | +13,404 | $0.34 | $4,598 | 129,173 | Feb 14, 2025 |
| Feb 12, 2025 | XFOR X4 Pharmaceuticals, Inc | AGrant or award Common Stock | +600,000 | $0.00 | $0 | 729,173 | Feb 14, 2025 |
| Jan 23, 2025 | XFOR X4 Pharmaceuticals, Inc | AGrant or award Common Stock | +74,773 | $0.00 | $0 | 123,282 | Jan 27, 2025 |
| Jan 24, 2025 | XFOR X4 Pharmaceuticals, Inc | SOpen-market sale Common Stock10b5-1 | -29,159 | $0.45 | $13k | 94,123 | Jan 27, 2025 |
Questions about Mark Baldry
Answered from the filings on this page, as of the latest one.
Is Mark Baldry buying or selling?
Not in the last 12 months. Mark Baldry's latest open-market trade on SEC Form 4 was bought $2,561 of XFOR on May 16, 2025.
How did Mark Baldry's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Baldry has 0.
Where does Mark Baldry file Form 4?
Mark Baldry has filed Form 4 at XFOR (X4 Pharmaceuticals, Inc) as Chief Commercial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.